NCT05870709 (LOCATE-HF) is a clinical trial of sacubitril/valsartan in Heart Failure, sponsored by Novartis Pharmaceuticals.

Who is sponsoring NCT05870709?

NCT05870709 is sponsored by Novartis Pharmaceuticals.

What drugs are being tested in NCT05870709?

Interventions in NCT05870709: sacubitril/valsartan.

What condition does NCT05870709 study?

NCT05870709 studies Heart Failure.

Is NCT05870709 still recruiting?

NCT05870709 is currently withdrawn. Last updated 6 July 2023.

Last reviewed 2023-07-06 · How we verify

NCT05870709: LOCATE-HF

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Real World, Pharmacy-assessed Adherence to New Onset Entresto® (Sacubitril/Valsartan) in Patients With Chronic Heart Failure

Withdrawn Last updated 6 July 2023

What this trial tests

trial testing sacubitril/valsartan in Heart Failure. Withdrawn.

Timeline

15 May 2023

Primary endpoint
31 October 2024

31 October 2024

Quick facts

Lead sponsor	Novartis Pharmaceuticals
Status	Withdrawn
Study type	OBSERVATIONAL
Start date	15 May 2023
Primary completion	31 October 2024
Estimated completion	31 October 2024

Drugs / interventions tested

sacubitril/valsartan

Conditions studied

Heart Failure — all drugs for Heart Failure →

Sponsor

Novartis Pharmaceuticals — full company profile →

Who can join

Adults 18 to 99, any sex, with Heart Failure. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, non-interventional, single arm cohort study with prospective collection of primary data via pharmacists in community pharmacies to describe adherence to sacubitril/valsartan in study patients at the end of the study. Eligible patients with newly prescribed sacubitril/valsartan will be observed in pharmaceutical routine.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of sacubitril/valsartan

Trials testing the same drug.

NCT06149104 — A Safety Study of Sacubitril/Valsartan in Japanese Pediatric Patients With Heart Failure Due to Systemic Left Ventricle · Phase 3 · completed
NCT05613140 — Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure · completed
NCT06218199 — Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts · Phase 4 · recruiting
NCT04637555 — Open-label Extension Study for CLCZ696G2301 (PARADISE-MI) · Phase 3 · withdrawn
NCT04743063 — Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty · unknown

Other recruiting trials for Heart Failure

Currently open trials in the same condition.

NCT06118983 — Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF) · NA · recruiting
NCT07496372 — Efficacy and Safety of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) in Advanced Heart · Phase 3 · recruiting
NCT07527156 — Prolonged Nasogastric Administration of Ketones in Decompensated Heart Failure · Phase 4 · recruiting
NCT07263035 — Urine Sodium-Driven Diuretic Adjustment Strategy in Acute Decompensated Heart Failure · Phase 4 · recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting

Other Novartis Pharmaceuticals trials

Trials by the same sponsor.

NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05870709 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
Last refreshed: 6 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05870709.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing